| |
| |
|
| Insider
Information: |
Papadopoulos Stelios |
| Relationship: |
Director, 10% Owner |
| City: |
Gaithersburg |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
4,592,750 |
|
|
Indirect Shares
|
4,643,486 |
|
|
| Direct
Value |
$32,049,392 |
|
|
|
Indirect Value
|
$32,648,514 |
|
|
| Total
Shares |
9,236,236 |
|
|
| Total
Value |
$64,697,906 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -56.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genvec Inc |
GNVC |
Director |
2003-08-21 |
305,840 |
|
0 |
Premium* |
|
|
Anadys Pharmaceuticals Inc |
ANDS |
Director |
2007-09-14 |
814,206 |
2004-03-25 |
1,995,374 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director |
2006-02-06 |
35,930 |
2006-02-06 |
0 |
Premium* |
|
|
Biogen Idec Inc |
BIIB |
Director |
2022-06-15 |
10,095 |
2022-06-15 |
28,206 |
Premium* |
|
|
Exelixis Inc |
EXEL |
Director |
2024-05-20 |
1,260,578 |
2017-09-22 |
0 |
Premium* |
|
|
Bg Medicine, Inc. |
BGMD |
Director |
2013-01-30 |
1,187,713 |
2011-02-09 |
0 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
|
2024-03-14 |
978,388 |
2014-12-12 |
0 |
Premium* |
|
|
Eucrates Biomedical Acquisition ... |
EUCR |
Director, 10% Owner |
|
0 |
2020-11-24 |
2,619,906 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2013-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,305 |
14,235 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2014-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,305 |
15,540 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2014-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
69,444 |
1,213,400 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2014-12-12 |
4 |
OE |
$0.38 |
$57,000 |
D/D |
150,000 |
150,000 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2015-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,040 |
16,580 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2015-07-27 |
4 |
B |
$304.78 |
$3,048,775 |
I/I |
10,000 |
5,000 |
2.1 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2015-08-07 |
4 |
OE |
$0.38 |
$78,801 |
D/D |
50,677 |
200,677 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2016-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,071 |
1,228,471 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2016-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,590 |
18,170 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-03-20 |
4 |
OE |
$10.53 |
$105,300 |
D/D |
10,000 |
1,238,471 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-03-20 |
4 |
S |
$21.66 |
$216,600 |
D/D |
(10,000) |
1,228,471 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-03-21 |
4 |
B |
$1.20 |
$239,800 |
D/D |
200,000 |
400,677 |
2.39 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-03-22 |
4 |
B |
$1.23 |
$368,100 |
D/D |
300,000 |
700,677 |
2.39 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
5,843 |
1,234,314 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Director |
• • – |
2017-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,740 |
19,946 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-07-25 |
4 |
B |
$0.91 |
$910,000 |
D/D |
1,000,000 |
1,770,677 |
2.39 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-09-18 |
4 |
S |
$27.76 |
$2,004,550 |
D/D |
(72,210) |
1,162,104 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-09-19 |
4 |
S |
$27.63 |
$3,530,838 |
D/D |
(127,790) |
1,034,314 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2017-09-22 |
4 |
S |
$25.40 |
$254,000 |
I/I |
(10,000) |
0 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$86,000 |
D/D |
96,629 |
1,797,306 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-03-02 |
4 |
OE |
$7.97 |
$119,550 |
D/D |
15,000 |
1,049,314 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-03-02 |
4 |
S |
$24.05 |
$360,750 |
D/D |
(15,000) |
1,034,314 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-05-07 |
4 |
S |
$22.15 |
$332,250 |
D/D |
(15,000) |
1,034,314 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-05-07 |
4 |
OE |
$11.66 |
$174,900 |
D/D |
15,000 |
1,049,314 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
7,937 |
1,042,251 |
0 |
- |
|
85 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
